Magnesium supplementation in cancer patients under cisplatin treatment

Clinical trial of oral magnesium oxide supplementation in prevention of cisplatin-induced hypomagnesaemia in cancer patients in Rasoul Akram hospital of Tehran university of medical sciences

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201112048299N1

Enrollment

Registered

2012-08-13

Start date

2009-12-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Hypomagnesaemia. Condition 2: Cancer types. Hypomagnesaemia (Disorders of magnesium metabolism Malignant neoplasms of lip, oral cavity and pharynx, Malignant neoplasms of digestive organs, Malignant neoplasms of respiratory and intrathoracic organs, Malignant neoplasms of bone and articular cartilage, Malignant neoplasms of mesothelial and soft tis

Interventions

Intervention 1: Patients in intervention group got magnesium oxide supplement (21CENTURY magnesium oxide 250 mg tablet)* according to Cisplatin dose (for Cisplatin dose up to 50 mg/m², 500 mg/day magn

Prevention

Patients in intervention group got magnesium oxide supplement (21CENTURY magnesium oxide 250 mg tablet)* according to Cisplatin dose (for Cisplatin dose up to 50 mg/m², 500 mg/day magnesium oxide, for

Patients in control group did not get any supplement.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: cancer diagnosis, beginning chemotherapy with Cisplatin drug, absence of renal disease and alcoholism, leukemia, non-consumption of drugs such as diuretics, aminoglycosides, cyclosporine and amphotericin B Exclusion criteria: death before end of treatment

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum magnesium level. Timepoint: Before starting every course of chemotherapy. Method of measurement: Biochemical analysis.	—

Secondary

Measure	Time frame
Serum Creatinin level. Timepoint: Before starting every course of chemotherapy. Method of measurement: Biochemical analysis.;Serum Urea level. Timepoint: Before starting every course of chemotherapy. Method of measurement: Biochemical analysis.;Serum Calcium level. Timepoint: Before starting every course of chemotherapy. Method of measurement: Biochemical analysis.;Serum Potassium level. Timepoint: Before starting every course of chemotherapy. Method of measurement: Biochemical analysis.;Serum Sodium level. Timepoint: Before starting every course of chemotherapy. Method of measurement: Biochemical analysis.	—

Measure

Time frame

Serum Creatinin level. Timepoint: Before starting every course of chemotherapy. Method of measurement: Biochemical analysis.;Serum Urea level. Timepoint: Before starting every course of chemotherapy. Method of measurement: Biochemical analysis.;Serum Calcium level. Timepoint: Before starting every course of chemotherapy. Method of measurement: Biochemical analysis.;Serum Potassium level. Timepoint: Before starting every course of chemotherapy. Method of measurement: Biochemical analysis.;Serum Sodium level. Timepoint: Before starting every course of chemotherapy. Method of measurement: Biochemical analysis.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Zarif Yeganeh

Research Institute for Endocrine Sciences of Shahid Beheshti University of Medical Sciences

m_zarifyeganeh@yahoo.com+98 21 2243 2503

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026